Marbet G A
Hämostaselabor DZL, Kantonsspital Basel.
Praxis (Bern 1994). 1999 Apr 29;88(18):802-7.
Extensive review articles and recent comparative clinical studies demonstrate that low molecular weight heparins are able to cover successfully the prophylactical and therapeutical indications of classical unfractionated heparin. Similar antithrombotic mechanisms but better pharmacokinetic properties are the reason why low molecular weight heparins are about to become the "better heparin". They are the first choice for acute prophylaxis and treatment of venous thromboembolism, for clot prevention in hemodialysis and as good or better than unfractionated heparin for the management of unstable angina pectoris. In the near future studies may prove their antithrombotic efficacy in other parts of the arterial circulation.
大量综述文章和近期的比较临床研究表明，低分子量肝素能够成功满足传统普通肝素的预防和治疗适应症。相似的抗血栓形成机制但更好的药代动力学特性，是低分子量肝素即将成为“更佳肝素”的原因。它们是急性静脉血栓栓塞症预防和治疗、血液透析中预防凝血的首选药物，并且在治疗不稳定型心绞痛方面与普通肝素效果相当或更佳。在不久的将来，研究可能会证实它们在动脉循环其他部位的抗血栓疗效。
